Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 135 of 5804
-
New hope for kids with deadly brain cancer: targeted drug trial launches
Disease control Not yet recruitingThe goal of this study is to determine the efficacy of the study drugs tovorafenib to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (MAPK) that this drug targets. The main question t…
Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug gilteritinib may beat standard therapy in preventing AML relapse after transplant
Disease control Recruiting nowThe study population consisted of FLT3-ITD-mutated AML patients who were FLT3-ITD-positive before allogeneic hematopoietic stem cell transplantation. This open-label, randomized, controlled trial enrolled participants and randomly assigned them in a 1:1 ratio to either the experi…
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC
-
New hope for pancreatic cancer: targeted drug combo enters human trials
Disease control Not yet recruitingThe goal of this clinical trial is to assess the safety and efficacy of ANO31905 in combination with chemotherapy as the first-line treatment for subjects with CLDN18.2-positive locally advanced unresectable or metastatic pancreatic cancer.
Phase: PHASE1, PHASE2 • Sponsor: Anova Innovation Limited • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can a One-Two punch wake up and destroy hidden HIV?
Disease control Not yet recruitingThis study aims to investigate the safety and preliminary efficacy of an innovative therapeutic strategy combining chidamide with NKG2D-directed chimeric antigen receptor natural killer (CAR-NK) cells in individuals living with HIV. The approach is predicated on the "shock and ki…
Phase: PHASE1, PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo therapy aims to shrink rectal tumors before Surgery—Could spare some patients the knife
Disease control Not yet recruitingStandard treatment for patients with proficient mismatch repair (pMMR) / microsatellite stable (MSS) locally advanced rectal cancer (LARC) consists primarily of neoadjuvant chemoradiotherapy followed by radical surgery. Several studies (including the UNION, STELLAR, TORCH, and SP…
Phase: PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Triple threat: radiation plus Immuno-Chemo shows promise for lung cancer
Disease control Not yet recruitingThis is an open-label, randomized, controlled, multicenter phase III clinical trial designed to evaluate the efficacy and safety of spatially fractionated stereotactic body radiotherapy (SF-SBRT) combined with toripalimab and platinum-based chemotherapy versus toripalimab combine…
Phase: PHASE3 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New antibody may offer safer shield against transplant complications
Disease control Recruiting nowAcute graft-versus-host disease remains a major complication after haploidentical hematopoietic stem cell transplantation. Methotrexate is commonly used as part of graft-versus-host disease prophylaxis, but it may be associated with delayed hematopoietic recovery and transplant-r…
Phase: PHASE3 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New combo therapy aims to stop liver cancer from coming back after surgery
Disease control Not yet recruitingThis study is designed to evaluate the efficacy and safety of sintilimab-bevacizumab doublet combined with FOLFOX-HAIC and TACE as the perioperative adjuvant therapy in surgical resection to hepatocellular carcinoma with high-risk features. (1) Evaluate for some high-risk patient…
Phase: PHASE1, PHASE2 • Sponsor: BinYong Liang • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Surgery plus drugs may extend life in advanced liver cancer
Disease control Not yet recruitingThis study will evaluate whether resection of the primary liver tumor, in addition to standard first-line systemic therapy, improves survival in patients with hepatocellular carcinoma that has spread outside the liver but still has a resectable primary intrahepatic tumor. Partici…
Phase: NA • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Mind-Controlled tech: brain implant trial aims to restore independence for paralysis patients
Disease control Recruiting nowThis is a prospective, open-label, multi-center, single-arm study to evaluate the efficacy and safety of an implantable wireless brain-machine interface (BMI) system in patients with spinal cord injury. Eligible participants will undergo screening after signing informed consent, …
Phase: NA • Sponsor: Shanghai StairMed Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo aims to boost cervical cancer treatment
Disease control Recruiting nowThis study mainly evaluated the efficacy and safety of Cadonilimab combined with chemotherapy followed by concurrent chemoradiotherapy versus standard concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer.
Phase: PHASE3 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug aims to outperform chemo in tough bladder cancer
Disease control Recruiting nowResearchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sa…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Salt water infusion could boost brain injury recovery
Disease control Recruiting nowThe purpose of this study is to demonstrate the efficacy of early continuous intravenous infusion of hypertonic saline solution (HSS) to improve survival and independence in daily life activities (at 6 months) of patients with traumatic brain injury at high risk of intracranial h…
Phase: PHASE3 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Ambulance steroid shot may cut heart attack deaths, large trial underway
Disease control Recruiting nowBACKGROUND Myocardial reperfusion with the use of primary percutaneous coronary intervention (PCI) including stent implantation is the most efficacious treatment for patients with (STEMI) and improves prognosis significantly. Due to continuous improvements in the treatment, the m…
Phase: PHASE3 • Sponsor: Thomas Engstrom • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New shot could soothe severe eczema in teens
Disease control Not yet recruitingThis is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of MG-K10 monotherapy in adolescents with moderate-to-severe atopic dermatitis (AD)
Phase: PHASE3 • Sponsor: Shanghai Mabgeek Biotech.Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New drug cocktail shows promise for untreated leukemia patients
Disease control Recruiting nowThis is a multicenter, prospective, single-arm clinical study designed to evaluate the efficacy and safety of the VA-CIG regimen (venetoclax combined with azacitidine, idarubicin, low-dose cytarabine and granulocyte colony-stimulating factor \[G-CSF\]) as induction therapy for pr…
Phase: PHASE2 • Sponsor: Beijing 302 Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New clotting factor aims to stop bleeding in severe hemophilia a
Disease control Recruiting nowThe indication for this product is to control bleeding in patients with hemophilia A (congenital deficiency of factor VIII). The primary objective: Evaluation of the efficacy of recombinant human coagulation factor VIII-Fc fusion protein for injection (FRSW107) as an on-demand …
Phase: PHASE3 • Sponsor: Hangzhou Gensciences Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New lupus drug shows promise in major trial
Disease control Recruiting nowThis study will evaluate the efficacy and safety of MIL62 compared with placebo in participants with systemic lupus erythematosus.
Phase: PHASE3 • Sponsor: Beijing Mabworks Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Bladder cancer patients may avoid surgery with new drug combo
Disease control Recruiting nowThe goal of this clinical trial is to learn whether a combination of two chemotherapy drugs, Gemcitabine and Docetaxel, can treat high-grade non-muscle-invasive bladder cancer (HG-NMIBC) in adults whose cancer failed conventional BCG therapy. The drugs are given directly into the…
Phase: PHASE2 • Sponsor: Michael A. O'Donnell • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New hope for ph+ ALL: targeted combo shows promise
Disease control Recruiting nowThis is an open-label, prospective clinical cohort study evaluating the efficacy and safety of reduced-intensity chemotherapy combined with targeted therapy and immunotherapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC